Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have inked an agreement offering Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for cancer treatment to be discovered and developed at the Lead Discovery Center.
The Broad Institute of MIT and Harvard has joined discussions to form a non-exclusive CRISPR-Cas9 joint licensing pool coordinated by MPEG LA, an organization that operates patent pool licensing programs in various institutions and countries.
Shield Therapeutics and Ewopharma have entered into an exclusive sale, supply, distribution and marketing agreement for Feraccru in Switzerland.
Celgene has agreed to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317 for the treatment of solid tumor cancers.
Alexion Pharmaceuticals has signed a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England based on a Managed Access Agreement (MAA), which provides access to Strensiq (asfotase alfa) for patients in England with pediatric-onset hypophosphatasia (HPP), regardless of their current age.
CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to filing an Investigational New Drug (IND) application next year.
Servier and Transgene have signed a research agreement on the application of viral vectorization technology for the production of allogenic CAR-T cell therapies.
NICE's Cancer Drugs Fund (CDF) is driving early access to new drugs for lung cancer and sarcoma for NHS patients in England.
Healthcare and life science firm Arix Bioscience has acquired a stake in Mitoconix Bio as part of an oversubscribed $20m Series A financing round.
Repare Therapeutics has secured $68m in a Series A financing round which it will use to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.